Back to List View Graph View

CD44

CD44 is a multifunctional transmembrane glycoprotein and cell surface receptor broadly expressed across mammalian tissues, where it plays central roles in cell adhesion, migration, proliferation, and survival.

Where the papers sit

14 papers from the last 6 months study CD44 directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 2 human data · 11 preclinical · 1 unclassified

Themes 3 themes

  • Hyaluronic Acid Drug Delivery

    Hyaluronic acid platforms are moving toward CD44-targeted, stimuli-responsive delivery of cytotoxic, anti-inflammatory and immunomodulatory agents. Glutathione, pH and charge responsiveness are used to release doxorubicin, podophyllotoxin and other payloads selectively. Combination designs seek ferroptosis, apoptosis, sonodynamic effects or macrophage reprogramming rather than single mechanisms. The approach is expanding across cancer, chronic lung disease and psoriasis, with targeting and reduced off-target toxicity as recurring goals.

    8 papers · 57.1%

  • CD44 Signaling in Breast Cancer

    CD44-directed treatment is being linked to metabolic vulnerabilities in triple-negative breast cancer. Adapalene inhibits CD44 activity, while KYNU blockade with KS79356 suppresses TNF-α/NFκB-CD44-Akt signaling and tumor progression. Tryptophan metabolism and kynureninase activity recur as potential therapeutic entry points. Exosome profiling is also moving toward blood-based characterization of breast cancer subtypes.

    3 papers · 21.4%

  • Immune Target Discovery

    Microbiota-derived metabolites and chemokine circuits are being connected to immune dysfunction in liver disease. Butyrate-associated targets, CCL5 signaling and hepatocyte–CD44+ pDC crosstalk recur as possible routes to restore antibacterial immunity in cirrhosis and primary biliary cholangitis. Macrophages and other immune populations remain central candidate effectors. Spatial CRISPR screening is adding functional resolution to target discovery, although validation of these candidates remains open.

    3 papers · 21.4%

Papers

The 14 papers from the last 6 months that study CD44 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Hyaluronic Acid Drug Delivery (8)
  1. Tumor-responsive hyalo-chitosan nanoparticles for targeted delivery of andrographolide in CD44+ breast cancer cells. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 27 Sept 2026 PMID 42801978
  2. CD44-Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid-Coated Polymersomes for Synergistic Anti-Inflammatory Therapy. ChemMedChem · 23 Jul 2026 PMID 42493250
  3. CD44-targeted hyaluronic acid-podophyllotoxin micelles with dual-stimuli responsiveness for lung cancer therapy. International journal of pharmaceutics · 23 Jul 2026 PMID 42492642
  4. Hyaluronic acid-modified nanoparticles for chemo/sonodynamic therapy: Maximizing antitumor efficacy through the induction of ferroptosis and apoptosis. International journal of biological macromolecules · 5 Jul 2026 PMID 42402299
  5. Dual-trigger hyaluronic acid nanoprodrug incorporating a 2-nitrobenzenesulfonyl linker for CD44-targeted and glutathione-responsive drug delivery. International journal of pharmaceutics · 4 Jul 2026 PMID 42401301
  6. Glutathione-Responsive Inhalable Nanotherapeutics for Targeted Macrophage Reprogramming in Chronic Obstructive Pulmonary Disease. Biomacromolecules · 18 Jun 2026 PMID 42312473
  7. A charge-reversible hyaluronic acid prodrug nanoplatform for synergistically enhanced tumor-targeted doxorubicin delivery. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 6 Jun 2026 PMID 42250822
  8. Multifunctional self-assembled nanoparticles loaded into immunomodulatory microneedles for synergistic therapy of psoriasis. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235198
CD44 Signaling in Breast Cancer (3)
  1. KS79356, a novel kynureninase inhibitor, suppresses triple-negative breast cancer progression by attenuating the TNF-α/NFκB-CD44-Akt signaling axis. Medical oncology (Northwood, London, England) · 29 Aug 2026 PMID 42667332
  2. A Droplet-Microarray Platform for Multiplex Profiling of Breast Cancer Exosome Subtypes in Patients' Blood Plasma Samples. Small (Weinheim an der Bergstrasse, Germany) · 7 Jul 2026 PMID 42410964
  3. Adapalene inhibits the activity of CD44, a cancer stem cell biomarker in Triple negative breast cancer. Molecular biology reports · 3 Jul 2026 PMID 42397497
Immune Target Discovery (3)
  1. Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis. PloS one · 13 Aug 2026 PMID 42594087
  2. Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44+pDC crosstalk. Journal of hepatology · 1 Jul 2026 PMID 42385859
  3. Uncovering spatially resolved functional genomics with CRISPR screen sequencing. Cell · 26 May 2026 PMID 42190664

By study type

Human data, design not indexed (2)
  1. Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis. PloS one · 13 Aug 2026 PMID 42594087
  2. A Droplet-Microarray Platform for Multiplex Profiling of Breast Cancer Exosome Subtypes in Patients' Blood Plasma Samples. Small (Weinheim an der Bergstrasse, Germany) · 7 Jul 2026 PMID 42410964
Preclinical: animal, cell and lab studies (11)
  1. Tumor-responsive hyalo-chitosan nanoparticles for targeted delivery of andrographolide in CD44+ breast cancer cells. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 27 Sept 2026 PMID 42801978
  2. KS79356, a novel kynureninase inhibitor, suppresses triple-negative breast cancer progression by attenuating the TNF-α/NFκB-CD44-Akt signaling axis. Medical oncology (Northwood, London, England) · 29 Aug 2026 PMID 42667332
  3. CD44-Targeted Delivery of Melittin and Celecoxib via Hyaluronic Acid-Coated Polymersomes for Synergistic Anti-Inflammatory Therapy. ChemMedChem · 23 Jul 2026 PMID 42493250
  4. CD44-targeted hyaluronic acid-podophyllotoxin micelles with dual-stimuli responsiveness for lung cancer therapy. International journal of pharmaceutics · 23 Jul 2026 PMID 42492642
  5. Hyaluronic acid-modified nanoparticles for chemo/sonodynamic therapy: Maximizing antitumor efficacy through the induction of ferroptosis and apoptosis. International journal of biological macromolecules · 5 Jul 2026 PMID 42402299
  6. Dual-trigger hyaluronic acid nanoprodrug incorporating a 2-nitrobenzenesulfonyl linker for CD44-targeted and glutathione-responsive drug delivery. International journal of pharmaceutics · 4 Jul 2026 PMID 42401301
  7. Adapalene inhibits the activity of CD44, a cancer stem cell biomarker in Triple negative breast cancer. Molecular biology reports · 3 Jul 2026 PMID 42397497
  8. Glutathione-Responsive Inhalable Nanotherapeutics for Targeted Macrophage Reprogramming in Chronic Obstructive Pulmonary Disease. Biomacromolecules · 18 Jun 2026 PMID 42312473
  9. A charge-reversible hyaluronic acid prodrug nanoplatform for synergistically enhanced tumor-targeted doxorubicin delivery. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 6 Jun 2026 PMID 42250822
  10. Multifunctional self-assembled nanoparticles loaded into immunomodulatory microneedles for synergistic therapy of psoriasis. Colloids and surfaces. B, Biointerfaces · 3 Jun 2026 PMID 42235198
  11. Uncovering spatially resolved functional genomics with CRISPR screen sequencing. Cell · 26 May 2026 PMID 42190664
Unclassified: not yet indexed with MeSH (1)
  1. Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44+pDC crosstalk. Journal of hepatology · 1 Jul 2026 PMID 42385859